Immunocore (IMCR) presents data at ESMO demonstrating reduction in circulating tumor DNA while on tebentafusp is associated with OS in the Phase 2…

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

PRESS RELEASE

Immunocore presents data at the European Society for Medical Oncology (ESMO) Congress 2021 demonstrating a reduction in circulating tumor DNA (ctDNA) while on tebentafusp is associated with overall survival in the Phase 2 clinical trial

Linear correlation between the magnitude of ctDNA reduction on tebentafusp and improved overall survival

70% of evaluable patients had any ctDNA reduction and 14% had ctDNA clearance

Immunocore Holdings Plc (Nasdaq: IMCR), a late-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious and autoimmune disease, presented new data from the Companys lead program, tebentafusp (IMCgp100), at an oral presentation at the European Society for Medical Oncology (ESMO) Congress.

The findings presented by Alexander N. Shoushtari MD, medical oncologist at Memorial Sloan Kettering Cancer Center, demonstrated that reduction by Week 9 in circulating tumor DNA (ctDNA) while on tebentafusp is strongly associated with overall survival (OS). A majority (70%) of evaluable patients had any ctDNA reduction while 5% of patients had radiographic response per the RECISTv1.1 criteria. In addition, 14% of patients had complete ctDNA clearance and long OS; this included some patients with best response of stable or progressive disease. The analysis was based on the phase 2 trial of tebentafusp in HLA-A*02:01 positive, previously treated patients with metastatic uveal melanoma (mUM) (IMCgp100-102).

Uveal melanoma is characterized by a defined set of unique mutations that can be measured in the blood as free circulating tumor DNA, said David Berman, Immunocores Head of Research and Development, We found that the degree of ctDNA reduction from tebentafusp was strikingly correlated with overall survival. This association was observed even in patients whose tumor lesions appeared radiographically stable or progressing and suggests that clinical benefit from tebentafusp may occur even in patients who did not have a RECIST response.

The U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA) and the United Kingdoms Medicines and Healthcare Products Regulatory Agency (MHRA) have each accepted applications seeking the approval of tebentafusp for the treatment of HLA-A*02:01-positive adult patients with metastatic uveal melanoma based on the primary endpoint of overall survival (OS) from the Phase 3 study IMCgp100-202.

See more here:
Immunocore (IMCR) presents data at ESMO demonstrating reduction in circulating tumor DNA while on tebentafusp is associated with OS in the Phase 2...